. Author manuscript; available in PMC: 2021 Apr 1.

Published in final edited form as: Clin Rev Allergy Immunol. 2021 Apr;60(2):147–163. doi: 10.1007/s12016-020-08796-4

Table 4.

Status of SPMs in MS patient-derived biological fluids across different studies

S. no.	SPM	Biofluid	Outcome	Reference
1.	RvD1	CSF	Upregulated in highly active MS	[105]
2	NPD1	CSF	Detected only in highly active MS	[105]
3.	LXA₄	CSF	No change in patients with highly active MS	[105]
4.	LXB₄	CSF	Reduced in various clinical disease stages	[69]
5.	RvD3	CSF	Reduced in various clinical disease stages	[69]
6.	LXA₄	Plasma	A higher but non-significant increase in progressive MS patients	[70]
	LXB₄
	AT-LXA₄
7.	RvD1	Plasma	Increased in relapsing MS patients	[70]
7.	NPD1	Plasma	Increased in relapsing MS patients	[70]
8.	RvD5	Plasma	Slightly increased in relapsing MS but significantly increased in progressive MS	[70]
8.	PDX	Plasma		[70]

CSF cerebrospinal fluid, MS multiple sclerosis, RvD1–5 resolvin D series, LXA₄ lipoxin A₄, LXB₄ lipoxin B₄, AT-LXA₄ aspirin-triggered 15-epi-lipoxin A₄, NPD1 neuroprotectin D1, PDX protectin DX